The malaria inhibitor prediction (MAIP) platform is the result of a public-private collaboration whose aim is to develop a consensus model for predicting blood stage malaria inhibition. Five Pharma and not-for-profit partners trained a model (using code developed by EMBL-EBI) on their private datasets. The resulting models were combined by EMBL-EBI and made available through this public prediction platform.

The work to develop this platform is described in full in the article MAIP: A Prediction Platform for Predicting Blood-Stage Malaria Inhibitors.

More information and details on the input and output format files are given here.

One of our partners, the Medicines for Malaria Venture (MMV), is committed to supporting Open Innovation and taking drug discovery to the next level. Please contact us if you would like to test a sample of any compounds that you identify using MAIP in MMV’s Plasmodium falciparum asexual blood stage assay. Terms and conditions are available on the MMV website.

(0 B)